The Effects after Implementing a Drug Utilization Review System on Contraindicated Drug use: A Systematic Review

키워드

참고문헌 (36)

1. Hennessy S, "Drug utilization review", Pharmacoepidemiology, pp.439~453 (2006)
2. Fulda TR, "Current status of prospective drug utilization review", J Manag Care Pharm, 10, pp.433~441 (2004)
3. 윤성희, "Drug utilization review of mupirocin ointment in a Korean university-affiliated hospital", The Korean Journal of Internal Medicine, 30(4), pp.515~520 (2015), 대한내과학회[DOI]
4. Chen YF, "Incidence and possible causes of prescribing potentially hazardous", contraindicated drug combinations in general practice, 2005, pp.28, 67~80
5. Pilgrim JL, "Deaths involving contraindicated and inappropriate combinations of serotonergic drugs", Int J Legal Med, 125, pp.803~815 (2011)
6. Breton G, "Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function--the Three-City population-based study", Nephrol Dial Transplant, 26, pp.2852~2859 (2011)
7. Heaton A, "High frequency of itraconazole prescriptions with potentially interacting medications in a large health care plan", J Manag Care Pharm, 8, pp.199~203 (2002)
8. Jones JK, "Coprescribing and codispensing of cisapride and contraindicated drugs", JAMA, 286, pp.1607~1609 (2001)
9. Lyles A, "When Warnings Are Not Enough: Primary Prevention Through Drug Use Review: To avoid adverse drug interactions, clinical data should follow the patient in the same way that financial data do", Health Aff (Millwood), 17, pp.175~183 (1998)
10. Smalley W, "Contraindicated use of cisapride:impact of food and drug administration regulatory action", JAMA, 284, pp.3036~3039 (2000)
11. Wagner AK, "FDA drug prescribing warnings:is the black box half empty or half full?", Pharmacoepidemiol Drug Saf, 15, pp.369~386 (2006)
12. Moja L, "Effectiveness of computerized decision support systems linked to electronic health records: a systematic review and meta-analysis", Am J Public Health, 104, pp.e12~e22 (2014)
13. 송선옥, "Background and Data Configuration Process of a Nationwide Population-Based Study Using the Korean National Health Insurance System", Diabetes and Metabolism Journal, 38(5), pp.395~403 (2014), 대한당뇨병학회[DOI]
14. Goedecke T, "Measuring the impact of medicines regulatory interventions-Systematic review and methodological considerations", Br J Clin Pharmacol, 84, pp.419~433 (2018)
15. Vander Stichele R, "European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach", Br J Clin Pharmacol, 58, pp.419~428 (2004)
16. Goossens H, "Outpatient antibiotic use in Europe and association with resistance: a crossnational database study", Lancet, 365, pp.579~587 (2005)
17. Moher D, "Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015statement", Syst Rev, 4, pp.1~ (2015)
18. Heo JH, "Evaluation of the pilot program on the real-time drug utilization review system in South Korea", Int J Med Inform, 82, pp.987~995 (2013)
19. 이수옥, "병용금기, 연령금기 경고 등급화 방안과 DUR 처방변경률 분석", 약 학 회 지, 59(6), pp.278~283 (2015), 대한약학회
20. 이명현, "의원 외래환자의 약품비 변화 관련요인: 처방총액 절감 인센티브제도와 DUR 제도 시행 전후를 중심으로", 보건행정학회지, 22(4), pp.561~578 (2012), 한국보건행정학회
21. 김성옥, "의료급여 환자 대상 의약품 중복투약 관리프로그램이 약국약제비와 원외처방조제서비스 이용에 용에 미치는 영향", 보건경제와 정책연구, 20(1), pp.1~19 (2014), 한국보건경제정책학회
22. 김동숙, "의약품 처방·조제지원서비스(Drug Utilization Review)사업이 병용금기 처방률에 미치는 영향", 보건행정학회지, 24(2), pp.120~127 (2014), 한국보건행정학회[DOI]
23. Shin JY, "Dramatic decrease in fluoroquinolones in the pediatric population in Korea", Pharmacoepidemiol Drug Saf, 23, pp.1320~1324 (2014)
24. Shin JY, "Regulatory action and moderate decrease in methylphenidate use among ADHD diagnosed patients aged five and under in Korea", Regul Toxicol Pharmacol, 72, pp.244~248 (2015)
25. Yang JH, "The effect of the introduction of a nationwide DUR system where local DUR systems are operating--The Korean experience", Int J Med Inform, 84, pp.912~919 (2015)
26. Song I, "Trends in prescription of pregnancy-contraindicated drugs in Korea, 2007-2011", Regul Toxicol Pharmacol, 75, pp.35~45 (2016)
27. Song I, "Decrease in use of contraindicated drugs with automated alerts in children", Pediatr Int, 59, pp.720~726 (2017)
28. Seung Yeon Song, "Pediatric fluoroquinolone prescription in South Korea before and after a regulatory intervention: A nationwide study, 2007-2015", PLOS ONE, 12(5), pp.e0176420~ (2017), Public Library of Science (PLoS)[DOI]
29. Armstrong PW, "Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers", Eur Heart J, 16, pp.75~80 (1995)
30. Bryant AD, "Drug interaction alert override rates in the Meaningful Use era: no evidence of progress", Appl Clin Inform, 5, pp.802~813 (2014)
31. Nancy M. Allen LaPointe, "Relation of Patient Age and Mortality to Reported Contraindications to Early Beta-Blocker Use for Non–ST-Elevation Acute Coronary Syndrome", The American Journal of Cardiology, 104(10), pp.1324~1329 (2009), Elsevier BV[DOI]
32. Keenan RT, "Prevalence of contraindications and prescription of pharmacologic therapies for gout", Am J Med, 124, pp.155~163 (2011)
33. Stephen B. Soumerai, "Computer-Based Drug-Utilization Review — Risk, Benefit, or Boondoggle?", New England Journal of Medicine, 332(24), pp.1641~1645 (1995), Massachusetts Medical Society[DOI]
34. Kim JY, "Changes in prescription pattern, pharmaceutical expenditure and quality of care after introduction of reimbursement restriction in diabetes in Korea", Eur J Public Health, 28, pp.209~214 (2018)[DOI]
35. Mossialos E, "Regulating Pharmaceuticals In Europe: Striving for Efficiency, Equity and Quality", pp.1~2 (2004), McGraw-Hill Education
36. Maynard A, "Dilemmas in regulation of the market for pharmaceuticals", Health Aff (Millwood), 22, pp.31~ (2003)

관련 논문AI추천